Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandon Imber

Radiation Oncology New York, NY Doctor of Osteopathy

NPI 1275928871 CMS profile 1358835

1275 York Ave, Mskcc Dept Of Radiation Oncology, New York, NY 10065

Open in the dashboard

General payments

$44,301

49 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,711,680 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Brandon Imber of New York, NY is reported in the CMS Open Payments database as having received $44,301 across 49 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,711,680 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,326 21
2024 General $4,275 15
2023 General $11,518 9
2022 General $1,683 3
2021 General $2,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Imber
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Brandon Imber were reported at $24,326. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Brandon Imber Radiation Oncology median Middle half National median
2019 $0 $138 $48–$462 $163
2020 $0 $79 $26–$262 $114
2021 $2,500 $119 $37–$358 $132
2022 $1,683 $139 $43–$424 $149
2023 $11,518 $167 $57–$473 $160
2024 $4,275 $168 $56–$541 $164
2025 $24,326 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GT Medical Technologies, Inc $39,608 37 payments
  2. Telix Pharmaceuticals $3,657 6 payments
  3. Novartis Pharmaceuticals Corporation $1,022 5 payments
  4. Tempus AI, Inc $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $26,450 11 payments
  2. Travel and Lodging $10,073 13 payments
  3. Honoraria $4,450 3 payments
  4. Food and Beverage $3,329 22 payments
Products named General payments · program years 2021–2025
  1. GammaTile Cns $24,159 20 payments
  2. GammaTile Kxk $15,449 17 payments
  3. ILLUCCIX Prostate Cancer Diagnosis $3,560 4 payments
  4. ILLUCCIX Prostate Cancer Therapy $2,500 2 payments
  5. ILLUCCIX Prostate Cancer Diagnosis $168 1 payment
  6. XT CDX $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

96

Median for Radiation Oncology: 65

Drug cost

$710

Median for Radiation Oncology: $978

Branded share of claims

0%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dexamethasone Generic 61 $598
Pantoprazole Sodium Generic 17 $94
Lorazepam Generic 18 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$232,927

Medicare's payments for the services billed

Medicare patients

403

Average age 75

Services billed

2,748

216 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 68%
Arthritis 45%
Ischemic heart disease 33%
Diabetes 32%
Depression 27%
Chronic kidney disease 25%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record